- Based on feedback from the FDA, Otsuka Pharmaceutical Co. (OTCPK:OTSKY)(OTCPK:OTSKF) and development partner H. Lundbeck A/S (OTC:HLUKF)(OTCPK:HLUYY) will conduct a third Phase 3 clinical trial assessing brexpiprazole for the treatment of agitation in Alzheimer's disease patients. The first two Phase 3s were completed earlier this year.
- The FDA approved brexpiprazole, branded as REXULTI, in July 2015 for the treatment of schizophrenia and as adjunctive treatment of major depressive disorder.
Otsuka and Lundbeck not quite there with brexpiprazole in Alzheimer's-related agitation, new late-stage study planned
Recommended For You
More Trending News
About OTSKY Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
OTSKY | - | - |
Otsuka Holdings Co., Ltd. |